An observational study in HIV Infection, Acquired Immune Deficiency Syndrome and Oral Health Care, sponsored by Nantes University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by Nantes University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in Acquired Immunodeficiency Syndrome with a site in France — 18 open to participants now, 23 under way, 5 of them phase 3. Acquired Immunodeficiency Syndrome · France.
Among the 109 studies in Acquired Immunodeficiency Syndrome with a site in France, this one is the 3rd largest by planned enrollment of the 34 observational ones that give a count, is one of 5 that started in 2026, is one of 34 observational ones, reaches primary completion later than 12 of the 22 other live ones, and was the 106th registered.
3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →18 of the 109 studies in Acquired Immunodeficiency Syndrome with a site in France are open now. Recruiting first, the newest first:
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida · Sites in France
Ages 18+ · Women only
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 75+
Merck Sharp & Dohme LLC · Sites in France, United States, Argentina and 6 more countries
Ages 18+
Université de Reims Champagne-Ardenne · Sites in France
Ages 18+ · Healthy volunteers
Casper Rokx · Sites in France, Belgium, Germany and 7 more countries
Ages 18+ · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 21 · Phase 3 37 · Phase 4 4
First in 1994; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,603 is above the median of 289 across 504 observational studies indexed under Acquired Immunodeficiency Syndrome.
Median enrollment 368 across the 75 interventional studies, 250 across the 34 observational. Of the 76 that completed or were terminated, 38 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 109 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.
Nantes University Hospital has 3 studies filed under Acquired Immunodeficiency Syndrome — fewer than ten, so there is no comparison to draw.
8 of the studies in Acquired Immunodeficiency Syndrome with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07044297Phase 3Merck Sharp & Dohme LLCA Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) | 2027-07-22 |
| NCT07921472Centre de Recherches et d'Etude sur la Pathologie Tropicale et le SidaCohort of Women Living With HIV-1 and Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide | 2026-11-30 |
| NCT05300035ANRS, Emerging Infectious DiseasesPhase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control | 2026-12-10 |
| NCT05390424University Hospital, RouenScreening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood Spot | 2027-01 |
| NCT07062614University Hospital, ToulouseExploration of the Variability of Exposure to Antiretroviral Treatment in Hair With a View to Validating Its Value as a Diagnostic Tool for Partial and/or Total Non-compliance With Treatment | 2027-02-28 |
Add all 8 to your calendar (.ics) → With an account.
Among the 109 studies in Acquired Immunodeficiency Syndrome with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Dental care for people living with HIV has evolved with the widespread use of antiretroviral therapy, which has improved life expectancy and disease control. However, uncertainty remains about whether specific adaptations are still needed during dental procedures due to potential biological abnormalities that may increase infectious or bleeding risks.
This study aims to evaluate the proportion of patients living with HIV in the Pays de la Loire region who may require adapted dental management based on biological parameters such as immune status, hematological values, and comorbidities.
A retrospective descriptive study will be conducted using anonymized data from 5,603 patients followed in the COREVIH Pays de la Loire database. The results are expected to provide objective data to better inform dental practice and reduce unnecessary precautions or stigmatization in the management of patients living with HIV.
This is a retrospective descriptive observational study using anonymized data from patients living with HIV followed in the Pays de la Loire region. The dataset includes 5,603 individuals whose data were previously collected as part of routine clinical care and recorded in the Nadis medical database by healthcare professionals involved in HIV management.
Data were provided by the COREVIH Pays de la Loire in an anonymized format and include demographic characteristics (age, sex), HIV-related variables (viral load, duration since diagnosis, antiretroviral therapy status), co-infections (sexually transmitted infections and hepatitis B/C), biological parameters (CD4 lymphocyte count, neutrophil count, platelet count, hemoglobin level), and comorbidities (e.g., diabetes, hypertension, renal disease, cardiovascular conditions, depression).
The primary objective is to determine the proportion of patients presenting biological abnormalities that may increase the risk of infectious or hemorrhagic complications during invasive dental procedures.
Data analysis will consist of descriptive statistics, including frequencies and percentages for categorical variables. The study does not involve any intervention, additional data collection, or direct patient contact.
All data are fully anonymized prior to analysis, ensuring that participants cannot be identified. The study complies with applicable data protection regulations and is based on previously collected clinical data.
3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
This study's planned enrollment of 5,603 is above the median of 289 across 504 observational studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.
Compared within Acquired Immunodeficiency Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is HIV Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Adult patients living with HIV followed in hospital-based infectious diseases departments in France, identified retrospectively from routine clinical records and biological databases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients living with HIV included in a retrospective cohort using anonymized data from the COREVIH Pays de la Loire database. The study population includes adults followed in routine clinical care, with available demographic, clinical, biological, and comorbidity data used to assess factors relevant to dental management.
Other: HIV infection status and clinical characteristics
Observational assessment of clinical, biological, and comorbidity data in patients living with HIV, including CD4 count, viral load, hematological parameters, and associated conditions, collected from routine care without any intervention.
Proportion of Patients Requiring Adapted Dental Management
Percentage of patients living with HIV presenting at least one biological abnormality associated with increased risk of infectious or hemorrhagic complications during invasive dental procedures, including low CD4 count, neutropenia, thrombocytopenia, or anemia, based on routinely collected clinical data.
Time frame: At time of data extraction (retrospective baseline)
CD4 Cell Count Distribution
CD4 lymphocyte count (cells/mm³) distribution among patients, used to assess immune status. Lower values indicate greater immunosuppression.
Time frame: At time of data extraction (retrospective baseline)
Neutrophil Count Distribution
Neutrophil count (cells/mm³) measured from routine blood tests. Lower values indicate increased risk of infection.
Time frame: At time of data extraction (retrospective baseline)
Platelet Count Distribution
Platelet count (×10⁹/L) measured from routine blood tests. Lower values indicate increased bleeding risk.
Time frame: At time of data extraction (retrospective baseline)
Hemoglobin Level Distribution
Hemoglobin level (g/dL) measured from routine blood tests. Lower values indicate anemia.
Time frame: At time of data extraction (retrospective baseline)
Prevalence of Comorbidities
Percentage of patients presenting comorbid conditions (e.g., diabetes, cardiovascular disease, renal disease, depression) that may impact dental management.
Time frame: At time of data extraction (retrospective baseline)
Viral Load Status
Proportion of patients with detectable versus undetectable HIV viral load, based on routine clinical measurements.
Time frame: At time of data extraction (retrospective baseline)
Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acquired Immunodeficiency Syndrome →